Antifungal Susceptibilities of Candida Species Isolated to Clinical Samples

dc.contributor.authorKalkanlı, Nevin
dc.contributor.authorAtmaca, Selahattin
dc.contributor.authorÖzcan, Nida
dc.date.accessioned2025-02-22T14:13:30Z
dc.date.available2025-02-22T14:13:30Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Candidiasis is a skin, mucosal, and organ infection caused by Candida fungi, with Candida albicans being the most common. These infections pose significant morbidity and mortality risks, necessitating rapid identification and characterization methods for diagnosis and personalized antifungal therapy based on Candida’s pathogenic properties. Materials and Methods: Candida species isolated from diverse clinical samples from patients were included in this study. A total of 86 isolates were analyzed at the genus and species levels using mass spectrometry, while susceptibility profiles to amphotericin B (AmB), anidulafungin (AND), fluconazole (FLC), and voriconazole were regulated using the gradient test method. Results: Candida spp. were detected in 1254 clinical samples obtained from 736 patients. Antifungal susceptibility was tested on 86 isolated samples, including C. albicans, Candida glabrata, Candida tropicalis, Candida parapsilosis, Candida kefyr, Candida guilliermondii, and Candida krusei. The corresponding rates of resistance to AmB and FLC in C. albicans isolates were 2.2% and 13.3%. No resistance to AND was determined. Conclusion: Candida species C. albicans is the most regularly isolated, but infections from other Candida species have increased. No resistance to AND was observed, but species-specific resistance to other antifungal agents was identified, emphasizing the need for continuous monitoring.en_US
dc.identifier.doi10.4274/hamidiyemedj.galenos.2024.82713
dc.identifier.endpage156en_US
dc.identifier.issn2718-0956
dc.identifier.issue3en_US
dc.identifier.startpage148en_US
dc.identifier.trdizinid1279607en_US
dc.identifier.urihttps://doi.org/10.4274/hamidiyemedj.galenos.2024.82713
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/1279607
dc.identifier.urihttps://hdl.handle.net/11468/30032
dc.identifier.volume5en_US
dc.indekslendigikaynakTR-Dizin
dc.language.isoenen_US
dc.relation.ispartofHamidiye Medical Journalen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_TR_20250222
dc.subjectAntifungal susceptibilityen_US
dc.subjectfluconazoleen_US
dc.subjectvoriconazoleen_US
dc.subjectCandida sppen_US
dc.subjectanidulafungien_US
dc.titleAntifungal Susceptibilities of Candida Species Isolated to Clinical Samplesen_US
dc.typeArticleen_US

Dosyalar